Pasar al contenido principal

Single particle real-time tracking with positrons in cardiovascular diseases

RYC2023-043157-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelator

  • Herraiz-Pérez, Aitor
  • Rodríguez-San Pedro, Andrea
  • Casquero-Veiga, Marta
  • Cossío, Unai
  • Arias-Ramos, Nuria
  • Gutiérrez, Lucía
  • Romero-Sanz, Eduardo
  • Luján-Rodríguez, Víctor Manuel
  • Cerón, Carlos
  • Oteo, Marta
  • González-Paredes, Ana
  • López-Larrubia, Pilar
  • Rosales, Rafael T. M. de
  • Cortés-Canteli, Marta
  • Morcillo, Miguel A.
  • Ruíz-Cabello, Jesús
  • Pellico, Juan
  • Herranz, Fernando
Data availability: The datasets generated and/or analyzed during the current study are very large and complex, and are not easily shared via public repositories, but they are fully available from the corresponding author upon reasonable request., Radiopharmaceuticals that combine diagnostic and therapeutic isotopes are at the forefront of novel cancer treatments. A crucial element is the method of attaching radioisotopes to biomolecules using chelator-based techniques that are widely used clinically. Selection from available chelators is essential because this choice influences the physicochemical and biological characteristics of the final radiopharmaceutical. Numerous chelators exist because none fulfill all ideal conditions: rapid and complete binding to radiometals at low concentrations and with metallic impurities, high thermodynamic and kinetic stability in vivo, easy bioconjugation, and, key for this work, achieving these for many radiometals from the growing list of medical isotopes. We demonstrate how nanotechnology may change this. Ten nano-radiotracers were synthesized, incorporating radiometals such as 68Ga, 64Cu, 89Zr, 99mTc, 201Tl, 111In, 67Ga, 177Lu, 223Ra, and 225Ac into the nanoparticle core. The versatility of the platform was demonstrated through proof-of-concept experiments, including passive targeting in glioblastoma, active targeting of thrombosis, intratumoral radiotherapy in glioblastoma, and renal clearance optimization. This nanotracer addresses traditional challenges in radiopharmaceutical development, offering a single platform with consistent physicochemical and biological properties regardless of the radioisotope used for robust diagnostic and therapeutic applications., The authors thank funding from the Spanish Ministry of Science and Innovation (PDC2022-133493-100, RED2022-134299-T, PID2019-104059RB-100), Comunidad de Madrid (P2022/BMD-7333) and Conexion Nanomedicina CSIC. The authors thank the Sebastián Cerdán Biomedical NMR Facility of IIBM for their technical support. J. P. acknowledges financial support from the Ramon y Cajal program (Grant No. RYC2023-043157-I) funded by the MCIN/AEI/10.13039/501100011033 and the ESF “Investing in your future”., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelator

  • Herraiz, Aitor
  • Rodríguez-San-Pedro, Andrea
  • Casquero-Veiga, Marta
  • Cossío, Unai
  • Arias-Ramos, Nuria
  • Gutiérrez, Lucía
  • Romero-Sanz, Eduardo
  • Luján-Rodríguez, Víctor Manuel
  • Cerón, Carlos
  • Oteo, Marta
  • González-Paredes, Ana
  • López-Larrubia, Pilar
  • Rosales, Rafael T. M. de
  • Cortes-Canteli, Marta
  • Morcillo, Miguel A.
  • Ruiz-Cabello, Jesús
  • Pellico, Juan
  • Herranz, Fernando
Radiopharmaceuticals that combine diagnostic and therapeutic isotopes are at the forefront of novel cancer treatments. A crucial element is the method of attaching radioisotopes to biomolecules using chelator-based techniques that are widely used clinically. Selection from available chelators is essential because this choice influences the physicochemical and biological characteristics of the final radiopharmaceutical. Numerous chelators exist because none fulfill all ideal conditions: rapid and complete binding to radiometals at low concentrations and with metallic impurities, high thermodynamic and kinetic stability in vivo, easy bioconjugation, and, key for this work, achieving these for many radiometals from the growing list of medical isotopes. We demonstrate how nanotechnology may change this. Ten nano-radiotracers were synthesized, incorporating radiometals such as 68Ga, 64Cu, 89Zr, 99mTc, 201Tl, 111In, 67Ga, 177Lu, 223Ra, and 225Ac into the nanoparticle core. The versatility of the platform was demonstrated through proof-of-concept experiments, including passive targeting in glioblastoma, active targeting of thrombosis, intratumoral radiotherapy in glioblastoma, and renal clearance optimization. This nanotracer addresses traditional challenges in radiopharmaceutical development, offering a single platform with consistent physicochemical and biological properties regardless of the radioisotope used for robust diagnostic and therapeutic applications.